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Because of the morbidity and limited therapeutic options of autoimmune diseases, 
there is a high, and thus far, unmet medical need for development of novel treatments. 
Pemphigoid diseases, such as epidermolysis bullosa acquisita (EBA), are prototypical 
autoimmune diseases that are caused by autoantibodies targeting structural proteins of 
the skin, leading to inflammation, mediated by myeloid cells. To identify novel treatment 
targets, we performed cutaneous genome-wide mRNA expression profiling in 190 out-
bred mice after EBA induction. Comparison of genome-wide mRNA expression profiles 
in diseased and healthy mice, and construction of a co-expression network identified 
Sykb (spleen tyrosine kinase, SYK) as a major hub gene. Aligned, pharmacological SYK 
inhibition protected mice from experimental EBA. Using lineage-specific SYK-deficient 
mice, we identified SYK expression on myeloid cells to be required to induce EBA. 
Within the predicted co-expression network, interactions of Sykb with several partners 
(e.g., Tlr13, Jdp2, and Nfkbid) were validated by curated databases. Additionally, novel 
gene interaction partners of SYK were experimentally validated. Collectively, our results 
identify SYK expression in myeloid cells as a requirement to promote inflammation in 
autoantibody-driven pathologies. This should encourage exploitation of SYK and SYK-
regulated genes as potential therapeutic targets for EBA and potentially other autoanti-
body-mediated diseases.
Keywords: skin, autoimmunity, spleen tyrosine kinase, signal transduction, animal models, treatment, pemphigoid, 
epidermolysis bullosa acquisita
inTrODUcTiOn
In pemphigoid disease (PD), autoantibodies against defined structural proteins of the skin cause 
inflammation and subsequently subepidermal blistering (1, 2). During the last years, animal models 
of the PD epidermolysis bullosa acquisita (EBA) shaped our current understanding of the disease 
pathogenesis (3). In EBA, autoantibody-induced inflammation and subepidermal blistering are 
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initiated by binding of autoantibodies to their target antigen [type 
VII collagen (COL7)]. Subsequently, the complement cascade is 
activated (4–6). This and cytokine release permit a CD18/ICAM1-
dependent extravasation of Gr-1+ myeloid cells (7, 8). Within 
the skin, binding of myeloid cells to the immune complexes 
(ICs) located at the dermal–epidermal junction (DEJ) through 
specific Fc gamma receptors (FcγR) is unequivocally required to 
induce clinically manifest disease (9). The engagement of FcγR to 
skin-bound ICs triggers intracellular signaling, involving PI3K 
beta, AKT, p38 MAPK, ERK, Src family kinases, PDE4, CARD9, 
and RORα (10–15); ultimately leading to the release of reactive 
oxygen species (ROS) and proteases that facilitate inflammation 
and subepidermal blistering (7, 16).
To obtain further insights into EBA pathogenesis and to 
define novel treatment targets, we determined the whole-genome 
expression profile of 190 outbred mice of an advanced intercross 
line (17) after EBA induction. Of the identified hub genes, we 
functionally validated the spleen tyrosine kinase (Sykb, SYK). SYK 
is a non-receptor cytoplasmic enzyme that is mainly expressed 
in hematopoietic cells, which is essential in regulating cellular 
responses to extracellular antigens or antigen-immunoglobulin 
complexes (18, 19). As an important example, SYK acts down-
stream of activating FcγR and has thus emerged as a drug target 
for antibody-induced diseases, such as rheumatoid arthritis, 
where autoantibody-induced inflammation depends on FcγR. 
Yet, we recently described anti-inflammatory properties of SYK, 
triggered by binding of highly galactosylated ICs to FcγRIIB and 
dectin-1 to block the pro-inflammatory signaling triggered by 
G-protein coupled, membrane-bound receptors, exemplified by 
the C5aR1. The inhibition of signaling downstream of the C5aR1 
was mediated by tyrosine phosphorylation of the ITAM-like 
motif downstream of dectin-1 and transient phosphorylation of 
SYK (6). Thus, inhibition of SYK may have either anti- or pro-
inflammatory effects.
Hence, to address the functional role of the identified hub 
gene Sykb in experimental EBA, we performed an in-depth 
functional analysis using a variety of in vitro and in vivo model 
systems. Ultimately, we also verified the predicted gene network 
of the Sykb hub gene, leading to the identification of novel Sykb-
interacting genes.
MaTerials anD MeThODs
experiments with human Biomaterials
Foreskin and blood collections from healthy volunteers and 
patients were performed after written informed consent was 
obtained. All experiments with human samples were approved by 
the ethical committee of the Medical Faculty of the University of 
Lübeck and were performed in accordance with the Declaration 
of Helsinki. Skin biopsies from bullous pemphigoid (BP) patients 
for RNA expression profiling were obtained from five patients. 
The diagnosis was based on clinical presentation, detection of 
linear IgG and/or C3 deposits along the DEJ in perilesional skin 
biopsies by direct IF microscopy, and the detection of circulat-
ing anti-NC16A IgG by ELISA. Biopsies for RNA expression 
profiling were obtained from perilesional skin biopsies. Biopsies 
from corresponding, non-affected body sites served as controls. 
We included four female and one male BP patient. The mean 
age was 87  years (range 83–90  years). RNA expression profil-
ing was performed using the Human Gene 1.0ST (Affymetrix, 
Santa Clara, CA, USA). The complete dataset is currently under 
analysis. Herein, we focused the analysis on SKY and contrasted 
the expression levels of perilesional versus control skin. The 
data (CEL files) were processed using R oligo package. The data 
were corrected for background, and RMA normalization was 
performed. The normalized gene expression for SYK was used 
for accessing statistical significance.
animal experiments and immunization-
induced Murine eBa
C57Bl/6 (B6) mice were obtained from Charles River 
Laboratories (Sulzfeld, Germany). Mice expressing the cre gene 
on LysM [B6.129P2-Lyz2tm1(cre)Ifo/J], CD2 [B6.Cg-Tg(CD2-
cre)4Kio/J], and SYK-loxP-flanked (B6.129P2-Syktm1.2Tara/J) 
strains were obtained from the Jackson Laboratory (Bar Harbor, 
ME, USA) and were crossed to obtain cell lineage-specific 
Syk deletions. Mice were housed under specific pathogen-free 
conditions and provided standard mouse chow and acidified 
drinking water ad libitum. Animal experiments were approved 
by local authorities of the Animal Care and Use Committee 
(Kiel, Germany) and performed by certified personnel. Skin 
specimens from mice with immunization-induced EBA 
were obtained for unbiased mRNA expression profiling (see 
below) from a previously published study (17) using mice of 
an autoimmune-prone intercross outbred line (AIL mice). 
In brief, in order to generate a genetically diverse mouse line, 
EBA-susceptible (MRL/MpJ) and -resistant mice (NZM2410/J, 
Cast, and BXD2J), and the offspring of each generation were 
intercrossed for several generations. Genetic diversity of this so 
termed four-way, autoimmune-prone intercross mouse line, is 
reflected by the different morphological traits, including weight, 
tail length, or fur color. For the induction of experimental EBA, 
mice of the fourth generation were used.
generation of Microarray Data (mirnas/
genes) and Bioinformatics analysis
To monitor gene expression in the skin samples derived from AIL 
mice, total RNA was extracted from ears and hybridized to the 
Affymetrix Mouse Gene 1.0 ST Array (Affymetrix, Santa Clara, 
CA, USA). Raw data were processed using the “oligo” R pack-
age. The RMA method incorporated in the R package was used 
for normalization of probe intensities for all samples (20). The 
limma R package was used to assess differentially expressed genes 
between the EBA and wild-type mice. p-Values were corrected for 
multiple testing using Bonferroni correction. For gene expression 
profiling, low intensity probes were omitted to avoid putative 
false-positive signals and to lower the barrier for correction of 
multiple testing; these probes were filtered out using the median-
based method as implemented in the function “expressionBased-
filter” from the R DCGL package (21). Additionally, genes that 
did not show significant variations (p-value <  0.05) across the 
samples were filtered using the function “varianceBasedfilter” 
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in the same package. This function reduces the data to the most 
variable genes, which are presumably critical for the phenotype.
Ab Initio gene and network Predictions
For ab initio prediction, genes were clustered based on their 
co-expression profiles across different samples. The standard 
weighted correlation network (WGCNA) analysis procedure was 
used for cluster or module detection (22). A weighted adjacency 
matrix of pair-wise connection strengths (correlation coefficients 
of gene expression levels) was constructed using the soft-
threshold approach with a scale-independent topological power 
β = 6 (mRNA). Scale-free topology is a network whose degree of 
distribution follows a power law. For each probe, the connectivity 
was defined as the sum of all connection strengths with all others. 
Probes were aggregated into modules by hierarchical clustering 
and refined with the dynamic cut tree algorithm (23). Pearson cor-
relation coefficient was determined for each phenotype-module 
pair. The representative module expression profiles or module 
eigengene values are the first principal component of the gene 
expression profiles within a module. The correlation between 
the module eigengene and the sample trait of interest yields the 
eigengene significance as assessed by a correlation test. Modules 
were assigned different colors, with gray assigned to traits that 
could not be clustered in any other module. Additionally, partial 
least squares (PLS) regression was used to filter out false-positive 
interactions among the genes in each module (24). Briefly, PLS 
measures associations between each pair of genes under the 
influence of all other genes present in the dataset. Thus, it assigns 
the weight or numerical measurement for each edge/interaction 
for each pair of genes. The statistical significance of these edges 
is calculated using an empirical Bayes technique that uses a false 
discovery rate to assess significance (25). The DAVID web soft-
ware was used for pathway and gene ontology analysis (26). The 
software is based on the modified Fisher’s exact test and performs 
gene ontology analyses for the group of genes based on metabolic 
pathways, cellular components, and biological functions. Briefly, 
DAVID has pre-defined database in which various sets of genes 
are assigned to ontology terms such as metabolic pathways, cel-
lular compartments, and biological processes. DAVID provides a 
list of genes. Thereafter, DAVID calculates how many genes in the 
list are associated with a specific ontology term. The significance 
of the ontology term for these genes is calculated by the modified 
Fisher’s exact test. p-Values obtained for each ontology term are 
corrected for multiple testing using Bonferroni corrections.
ic-induced activation of 
Polymorphonuclear leukocytes (PMns)
Anti-coagulated (EDTA) blood collected from healthy blood 
donors was used for PMN isolation. Inhibition of ROS release in 
presence of BAY 61-3606 or PRT062607 (Selleckchem, Munich, 
Germany) was measured from IC- or C5a-activated PMNs using 
published protocols (27, 28).
ic-induced neutrophil activation
Peripheral heparinized blood was collected by venipuncture from 
healthy adult volunteers. Neutrophils were isolated as described 
previously using Percoll gradient centrifugation (29). Plate-bound 
immobilized immune complexes (iICs) were formed using a 
human serum albumin (HSA) antigen and a rabbit polyclonal 
anti-HSA-IgG1 antibody as described (30). Neutrophil activation 
was assayed by ROS release as described earlier.
Determination of cell surface Marker 
expression
Activation of PMN in the presence of BAY61-3606 was assayed 
using flow cytometry following established protocols (11, 31).
Measurement of PMn-Dependent Dermal–
epidermal separation
Ex vivo induction of dermal–epidermal separation was per-
formed as previously described (32). In brief, cryosections of 
human neonatal foreskin were incubated with recombinant 
anti-COL7 antibodies (32). After washing, slides were incubated 
for 2 h at 37°C with PMN, isolated by dextran sedimentation 
of freshly collected, heparinized blood from healthy volunteers. 
Here, sections were treated with either solvent or BAY61-3606 at 
the indicated concentrations. After fixation in 4% formaldehyde, 
slides were stained by H&E and examined by light microscopy 
for the presence of split formation within the DEJ zone. An 
observer unaware of the sections treatment has performed 
the later step. The degree of dermal–epidermal separation is 
expressed in relation to the length of the entire DEJ zone of 
each section. A detailed, step-by-step protocol for this assay has 
recently been published (33).
evaluation of PMn Viability
The viability of PMN in presence of BAY61-3606 was assayed 
using the FITC Annexin V Apoptosis Detection Kit II following 
the protocol provided by the manufacturer (BD Pharmigen™, 
Heidelberg, Germany). PMNs treated with UV light for 20 min 
served as positive control.
activation of neutrophils by iics and 
Western Blotting analysis
Neutrophils (5 × 106 in 1 ml of RPMI 1640 containing 10% heat-
inactivated FCS) were pre-incubated in presence or absence of 
250 ng/ml of the Syk BAY 61-3606 (medchemexpress, Princeton, 
NJ, USA) inhibitor for 20 min at 37°C. Subsequently, cells were 
added to wells coated with HSA-anti-HSA iIC and incubated 
for 15 min at 37°C. Following iIC stimulation, whole-cell lysates 
were prepared using TCA as previously described (34). Western 
blotting analysis was performed using Abs against human 
phospho-Akt (Thr308), phospho-p44/42 MAPK (ERK1/2 and 
Thr202/Tyr204), phospho-p38 MAPK (Thr180/Tyr182), and 
β-actin (all from Cell Signaling Technology) and probed with 
HRP-conjugated anti-rabbit or anti-mouse IgG (New England 
Biolabs, Beverly, MA, USA).
anti-cOl7 igg Transfer-induced Murine 
eBa and Treatment Protocol
To induce experimental EBA, mice were injected on alternating 
days with anti-COL7 IgG according to established protocols (35). 
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In brief, New Zealand white rabbits were s.c. immunized with 
250 mg murine von Willebrand factor A-like domain 2 protein 
that was suspended in CFA. The animals were boosted three times 
(at 13-day intervals) with the same protein preparation in IFA, and 
immune sera were characterized using immunofluorescent (IF) 
microscopy on cryosections of murine skin. IgG from immune 
and normal rabbit sera was purified using protein G affinity. 
Immune rabbit IgG or normal rabbit IgG (5 mg/injection) was 
injected s.c. into adult mice every second day for a total of six 
injections. Some mice were treated with BAY61-3606 dissolved 
in water. Mice were treated twice-daily p.o. with either solvent or 
BAY61-3606 at a dose of 25 or 50 mg/kg body weight. Treatments 
were initiated 1 day prior to the first anti-COL7 IgG injection, 
applied daily, and maintained until day 11. Clinical disease 
manifestation (expressed as the percentage of body surface area 
covered by EBA skin lesions) was determined 4, 8, and 12 days 
after the initial anti-COL7 IgG injection. From these data, the 
area under the curve (AUC) was used to calculate overall EBA 
severity.
immunofluorescence Microscopy
Biopsies of non-lesional skin were obtained 2 days after the last 
IgG injection, and IgG and C3 deposits were detected by direct 
immunofluorescence (IF) microscopy. The sections were probed 
with 100-fold diluted fluorescein isothiocyanate (FITC)-labeled 
antibodies specific to rabbit IgG (Dako, Glostrup, Denmark and 
Abcam plc, Cambridge, UK) and FITC-labeled anti-murine C3 
(MP Biomedicals, Solon, OH, USA).
Flow cytometry
For FACS analysis, healthy and lesional skin (both from cor-
responding anatomical sites) or blood was taken from mice 
after induction of experimental EBA. Single cell solutions 
from and blood were erythrocyte lysed with RB  cell lysis 
buffer (Miltenyi). The skin samples were cut into small pieces 
and digested with 345  mg/ml liberase (Roche) in RPMI for 
30 min/37°C. Single cells were stained for the following surface 
markers using standard FACS procedures: CD45-VioGreen 
(clone: 30F11), CD3-VioBlue (clone: 17A2), Ly6C-FITC (clone: 
1G7.G10), as well as Ly6G-APC Vio770 (clone: 1A8) and for 
blood CD19-APC (clone: 6D5), all from Miltenyi. For the sub-
sequent intracellular staining, the cells were fixed in fixation 
buffer (BioLegend) and permeabilized using the Intracellular 
Staining Perm Wash Buffer (BioLegend) following the manu-
facturer’s protocol. Intracellular staining was performed with 
SYK-PE (clone: 4D10.2). Cells were first gated for scatter 
(SSC-A/FSC-A) and singlets (FSC-H/FSC-A). The CD45+ gates 
were further analyzed for double-positive staining of SYK with 
the appropriate cell markers. Measurements were performed at 
the Miltenyi MacsQuant10, and data were analyzed with the 
MACSQuantify™ Software (version 2.8).
rT-Pcr
For gene expression analysis, TaqMan gene expression assays were 
purchased for the following transcripts: Plaur Mm01149438_m1, 
formyl peptide receptor 1 (Fpr1) Mm00442803_s1, CD3001b 
Mm01701741_m1, and Gapdh Mm99999915_g1 (Thermo Fisher 
Scientific, Waltham, MA, USA). RNA isolation, reverse transcrip-
tion, and real-time RT-PCR were performed as described (36). 
All data were normalized to Gapdh.
Western Blot analysis
Sections of frozen skin tissue (20 μm × 20 μm, either skin from 
immunization-induced EBA or corresponding healthy skin sec-
tions from Titermax™-injected controls) were scraped using a 
30 G syringe in 100 µl RIPA buffer and the protein concentra-
tion was measured using BCA protein assay following manu-
facturer’s protocols (Thermo Fisher Scientific). 15  µg protein 
were mixed in 5× Laemmli buffer and heated for 5 min at 95°C. 
Samples were separated by 10% SDS-PAGE and transferred to 
Immobilon-P membrane (Millipore, Bedford, MA, USA). The 
membrane was blocked for 1 h with TBS containing 0.1% Tween 
20 and 5% skim milk or 5% BSA and incubated for overnight 
(4°C) with the primary antibody (either SYK, clone D3Z1E 
(XP) or Rabbit mAb (Cell Signaling Technology, Danvers, MA, 
USA)) diluted in blocking buffer following the manufacturer’s 
instructions. Then the membrane was washed three times for 
5 min with TBS containing 0.1% Tween 20 and incubated with 
peroxidase-conjugated anti-rabbit secondary antibodies (Dako 
Deutschland GmbH, Hamburg, Germany) for 1  h at room 
temperature. After a washing step, the membrane was incubated 
for 1  min with ECL reagent (GE Healthcare Europe GmbH, 
Freiburg, Germany) and exposed to film. For reprobing with 
GAPDH antibody (Cell Signaling Technology), the membrane 
was washed twice in PBS, stripped for 10 min/37°C with strip-
ping buffer (GE Healthcare Europe GmbH), and washed three 
times for 5 min with TBS at room temperature. The relative SYK 
expression was calculated using ImageJ 1.51f (NIH, USA), and 
after background subtraction, the relative mean density of SYK/
GAPDH was calculated.
histopathology
Skin sections from corresponding anatomical sites were obtained 
2 days after the last IgG injection and prepared for examination by 
histopathology as described. The dermal neutrophil cell infiltrate 
was assessed semi-quantitatively using a score ranging from 0 to 3 
indicating no, mild, moderate, or severe infiltration, respectively 
(37).
statistical analysis
Unless otherwise noted, data were presented as mean ± SD. For 
comparisons of two groups, t-test or Mann–Whitney Rank Sum 
test was used when appropriate. For comparisons of more than 
two groups, ANOVA was used. For equally distributed data, 
one-way ANOVA followed by Bonferroni t-test for multiple 
comparisons was used; if the data were non-parametric, ANOVA 
on ranks (Kruskal–Wallis) was applied followed by Bonferroni 
t-test for multiple comparisons. In all tests, p < 0.05 was con-
sidered significant. All statistical analyses were performed using 
SigmaPlot 13.0 (Systat Software, Erkrath, Germany). The num-
ber of replicates for each experiment is detailed at the respective 
table/figure legends.
FigUre 1 | Differential co-expression of cutaneous mRNA expression levels in mice with experimental epidermolysis bullosa acquisita (EBA) identifies SYK as 
a major hub gene candidate. (a) We applied hierarchical clustering to cluster gene profiles and the dynamic cut tree method to combine branches and define 
co-expressed groups (modules) from the expression data. We found 12 modules and assigned them different colors, with gray used for genes that could not 
be assigned to any other module. To identify disease-related modules, we correlated module eigenvalues to the disease score for EBA severity and onset. 
Bar on the left corresponds to modules, and bar on the right displays the range for Pearson correlation (from −1 to 1). Data are derived from 68 mice with 
experimental EBA and 122 mice that remained healthy after type VII collagen immunization (17). (B) This image shows the gene network of the yellow 
module. Red lines display the interaction information from STRING database. Green lines display predicted interactions using domain interaction information. 
Dark blue lines represent PLSR-based interactions. Red circles indicate hub genes. (c) In patients with bullous pemphigoid, which shares a lot of similarity 
with the inflammatory EBA variant (2), we observed an increased SYK expression in perilesional, as compared to non-affected skin of corresponding 
anatomical sites.
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FigUre 2 | The SYK inhibitor BAY61-3606 protects mice from inflammation in antibody transfer-induced epidermolysis bullosa acquisita (EBA). (a) Treatment of 
mice with the SYK inhibitor BAY61-3606 almost completely protected them from induction of experimentally induced EBA by transfer of anti-type VII collagen IgG. 
Graph shows the mean (SD) body surface area affected by EBA skin lesions. (B) Overall disease activity was calculated as area under the curve (AUC) derived from 
individual mice in each of the treatment groups. Here, the mean (SD) of the AUC is shown. Individual dots represent disease severity (AUC) of individual mice 
(*p < 0.05, ANOVA with a Bonferroni post-test, n = 4–5 mice/group). Representative (c) clinical images of mice at day 12 of the experiment, (D) H&E-stained skin 
sections at 100× original magnification and (e) direct immunofluorescent microscopy staining for IgG and C3 from perilesional skin from solvent (left)- and 
BAY61-3606 (right)-treated animals (50 mg/kg dose) at 100× original magnification. For panels (c,D), data are based on five solvent and four (per concentration) 
BAY61-3606 treated animals.
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resUlTs
cutaneous mrna expression Profiling 
identifies sYK as One of the Major 
Differently expressed hub genes in 
experimental eBa
From mice of the outbred mouse line, 68 had clinically 
manifest EBA, while the remaining 122 mice were clinically 
healthy. Collectively, 1,038 mRNA probes were differentially 
expressed (adjusted p <  0.05, Bonferroni corrected). Of these, 
in samples from mice with clinically manifest EBA, 425 probes 
were downregulated and 613 were upregulated (Tables S1 and 
S2 in Supplementary Material). Next, a gene co-expression 
network of differentially expressed genes was constructed. Of the 
identified 12 modules, 8 showed a positive correlation, while 4 
negatively correlated with the EBA phenotype (Figure  1A). In 
the yellow module (r =  0.53, p-value =  2e−15, Figure 1B), 86 
interactions among the genes were validated by different statisti-
cal and database approaches (DOMINE, STRING, IPA databases, 
and PLS regression). Furthermore, four hub genes (degree of 
interaction >  10) were identified: Sykb, Ccrl2, Sell, and Trem3. 
FigUre 3 | Expression of CD45+ cells is increased, while proportional expression of SYK in leukocytes remains constant in lesional versus non-lesional skin in 
mice with experimental epidermolysis bullosa acquisita (EBA). (a) Specimen from lesional and non-lesional skin of mice injected with anti-type VII collagen IgG 
were analyzed for quality and quantity of dermal leukocyte infiltration. Yield of cells was higher from lesional skin compared to non-lesional skin from 
corresponding sites. Regarding the relative distribution of all leukocytes (CD45+) or subsets, we observed a difference regarding neutrophils (CD45+/Ly6G+; 
*p < 0.05, t-test). Hence, the relative distribution of the dermal infiltrate remains constant, while the absolute number of CD45+ cell increases in the skin of mice 
with experimental EBA. CD19+ cells were not observed in the skin samples (not shown). (B) Separately, expression of SYK was evaluated in CD45+ cells obtained 
from lesional and non-lesional skin. Relative expression of SYK in CD45+, CD45+/CD3+, CD45+/Ly6G+, and CD45+/Ly6C+ was identical in both groups. CD45+ 
cells from blood were used as positive control. (c) Representative FACS stainings from lesional skin, gated on CD45+/singlet cells. All data are based on four to 
five samples per group.
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We focused on the yellow module, specifically, Sykb because 
it has emerged as a therapeutic target in autoimmune diseases 
(38), and we observed an increased expression of SYK mRNA in 
perilesional skin of BP patients (Figure 1C). Our interest in SYK 
was further provoked by the contrasting effects of its blockade in 
mouse models and clinical trials in arthritis (39, 40).
Pharmacological sYK Blockade Dose-
Dependently and almost completely 
impairs induction of experimental eBa in 
Mice induced by Transfer of anti-cOl7 
igg
To validate the importance of SYK in EBA pathogenesis in vivo, 
we induced EBA in mice by anti-COL7 IgG transfer in the absence 
or presence of the SYK inhibitor BAY61-3606. Pharmacological 
blockade of SYK almost completely prevented the EBA-inducing 
activity of anti-COL7 IgG (Figures 2A–C). Consistent with the 
clinical observations, a reduction of dermal infiltration was 
observed in BAY61-3606-treated animals compared to the corre-
sponding anatomical sites in controls (Figure 2D). These changes 
were independent of alterations in IgG or C3 deposition along the 
DEJ (Figure 2E).
induction of anti-cOl7 igg-induced eBa 
requires sYK expression in cells of 
Myeloid, but not lymphoid linage
We next aimed to identify the cellular source of SYK. Because 
SYK is mainly expressed in hematopoietic cells (18), we focused 
on these. We first evaluated the cellular composition within 
the dermal infiltrate of experimental EBA, and simultaneously 
determined if lymphoid and/or myeloid cells within the infiltrate 
express SYK. Comparison of lesional versus non-lesional skin 
of mice injected with anti-COL7 IgG at the end of the experi-
ment showed a significant increase in cell numbers, while the 
proportion of most leukocytes within the dermis remained 
constant, the amount of Ly6G+ cells, which are key effector cells 
in experimental EBA, increased significantly (Figure 3A). In line 
with previous observations (41), all CD45+ cells expressed SYK, 
which, in addition, showed an identical proportional expression 
level in lesional and non-lesional skin (Figures 3B,C).
FigUre 4 | SYKfl/fl LysM-Cre mice are completely protected from induction of antibody transfer-induced epidermolysis bullosa acquisita (EBA). (a) Mean (SD) of 
affected body surface area after repetitive injections of anti-type VII collagen IgG into indicated mouse strains over the 12-day observation period (n = 3–7/strain). 
SYK wild type (+/+) and mice with only one SYK allele in their myeloid cells (SYKfl/+ LysM-cre) developed clinically manifested skin lesions, whereas mice deficient for 
SYK in myeloid cells (SYKfl/fl LysM-cre) were completely protected from induction of EBA (*p < 0.05, ANOVA with Bonferroni post-test). (B) The cumulative disease 
severity [area under the curve (AUC)] confirms complete protection of the SYKfl/fl LysM-cre mice (*p < 0.05, ANOVA with a Bonferroni post-test). Individual dots 
correspond to the AUCs of single mice. (c) Representative clinical images and H&E-stained sections from the back skin of indicated mouse strains (100× original 
magnification). All images shown are from day 12 of the experiment.
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To evaluate the functional impact of SYK expression on cells 
from the myeloid and lymphoid linage, floxed SYK mice were 
crossed with either LysM-Cre or CD2-Cre mice to selectively 
deplete SYK from myeloid or lymphoid cells. Notably, SYKfl/fl 
LysM-Cre mice were completely protected from EBA induction 
by anti-COL7 IgG transfer (Figures  4A–C); while transfer of 
anti-COL7 IgG-induced experimental EBA in SYKfl/fl CD2-Cre 
mice comparable to controls (Figures 5A–C). Changes in SYKfl/fl 
LysM-Cre mice were independent of changes in IgG or C3 deposi-
tion along the DEJ. Overall, this indicated that SYK expression in 
myeloid cells is an absolute requirement for induction of experi-
mental EBA.
The sYK inhibitor BaY61-3606 Dose-
Dependently Blocks ic-induced PMn 
activation
To further validate the contribution of SYK to IC-induced 
neutrophil activation, we stimulated neutrophils or PMNs with 
IgG IC in presence of different concentrations of different SYK 
FigUre 5 | SYKfl/fl CD2-Cre mice develop blistering in antibody transfer-induced epidermolysis bullosa acquisita (EBA). (a) Mean (SD) of the affected body surface 
area after repetitive injections of anti-type VII collagen IgG into the indicated mouse strains over the 12-day observation period (n = 3–9/strain). In contrast to the 
SYKfl/fl LysM-cre mice, mice with the specific deletion of SYK in lymphoid cells were completely susceptible to EBA induction. (B) The cumulative disease severity 
[expressed as the area under the curve (AUC)] calculated from the graphs in panel (a) is shown. The individual dots correspond to the AUCs of individual mice. (c) 
Representative clinical images and H&E-stained sections from the back skin of the indicated mouse strains (100× original magnification). All images shown are from 
day 12 of the experiment.
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inhibitors (BAY61-3606 or PRT062607). BAY61-3606 dose-
dependently reduced IgG IC-triggered release of ROS from 
PMNs (Figures 6A,B). Consistent with this finding, PRT062607 
significantly reduced IgG IC-triggered ROS (not shown). In some 
PD, i.e., EBA, anti-COL7 IgA is the only identified Ig class in 
approximately 30% of patients (42). Furthermore, anti-COL7 IgA 
induces PMN activation and subepidermal blistering in vitro (27, 
43). We thus assessed whether SYK blockade can also modulate 
ROS release from IgA IC-activated PMNs. Compared to IgG-IC-
activated PMNs, we observed an almost identical level of inhibition 
(Figures 6C,D). In line, BAY61-3606 also ablates ROS-dependent 
dermal–epidermal separation in cryosections of human skin 
incubated with anti-COL7 IgG and PMNs (Figures  6E–H). 
Regarding other neutrophil responses, inhibition of SYK normal-
ized activation-triggered CD66b expression, but had no effect on 
L-selectin sheading (Figures 6I–L). These effects of BAY61-3606 
were achieved at non-toxic concentrations (Figures 6M–P).
BaY61-3606 ablates signaling events in 
ic-activated PMn
Regarding the mechanisms downstream of SYK, we extended 
our previous findings that the IC-induced activation of PMNs 
FigUre 6 | Continued
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leads to the phosphorylation of ERK, AKT, and p38 (11). By 
adding BAY61-3606 to IC-activated PMNs, we show that SYK 
blockade leads to a reduction in the phosphorylation of ERK, 
AKT, and p38 in IC-activated PMNs (Figure 7). We next aimed 
to obtain novel insights into the pathways controlled by SYK. For 
this, PMNs were activated with ICs in the presence or absence 
of BAY61-3606, and expression levels of nine randomly genes 
from the predicted gene network controlled by SYK (Figure 1B) 
were evaluated. Two novel SYK-interacting genes, Plaur and 
Fpr1, were validated (Figure  8A). The latter is downregulated 
after the inhibition of SYK in IC-activated PMNs, while Plaur 
expression increased if SYK was inhibited. Furthermore, within 
the predicted co-expression network, several interacting partners 
of SKY were validated by curated databases (not shown); exam-
ples include Plek, Ppbp, Clec7a, and Nlrp3, which were predicted 
by the STRING database. Furthermore, the expression of Sykb, 
Plaur, and Fpr1 were determined in skin specimen from mice 
with and without experimental EBA. In line with the data shown 
in Figure 1, an increased expression of Sykb was noted in mice 
with experimental EBA. Similar differences among healthy and 
disease mice were observed for Plaur and Fpr1 (Figure  8B). 
RT-PCR data were confirmed using western blotting, detecting 
SYK (Figures 8C,D) almost exclusively in skin affected by EBA 
skin lesions.
DiscUssiOn
In an unbiased approach using whole-genome expression 
profiling, aiming to pinpoint novel therapeutic targets for the 
treatment of EBA and other PD, we identified Sykb as a hub gene 
in mice with experimental EBA. Based on this morphological 
observation, we hypothesized that inhibition of SYK may have 
FigUre 6 | Pharmacological inhibition of SYK blocks immune complex (IC)-induced activation of polymorphonuclear leukocytes (PMNs) in vitro and ex vivo. (a) 
Human PMNs were activated using IgG-ICs, and their activation was determined by measuring the release of reactive oxygen species (ROS). The data 
(n = 11–30/group) were normalized to IC-activated PMNs in the presence of solvent (water) and are displayed as the median (black line), the 27/75 percentiles 
(box), and the 5/95 percentiles (error bars). BAY61-3606 reduced the release of ROS from IC-activated PMNs in a dose-dependent manner (ANOVA on Ranks 
with Dunn’s post-test). (B) Representative ROS release expressed as counts per second (CPS) over the 60-min experimental period. (c) Human PMNs were 
activated using IgA-ICs, and their activation was determined by measuring the release of ROS. The data (n = 6/group) were normalized to the IC-activated PMNs 
in the presence of solvent (water) and are displayed as the median (black line), the 27/75 percentiles (box), and the 5/95 percentiles (error bars). BAY61-3606 
reduced the release of ROS from IC-activated PMNs in a dose-dependent manner (ANOVA on Ranks with Dunn’s post-test). (D) Representative ROS release 
expressed as CPS over the 60 min experiment. (e) BAY61-3606 also ablates dermal–epidermal separation in cryosections of human skin incubated with 
anti-type VII collagen (COL7) IgG and PMNs. The data are presented as the mean (boxes) and STD (error bars) and are based on five experiments per group. To 
calculate whether the effects of BAY61-3606 were significant, ANOVA with Ranks and Dunn’s post-test was used. (F–h) Representative images of the 
cryosection assay at a 200× original magnification showing (F) no dermal–epidermal separation in the sections incubated with normal human serum (NHS) and 
PMNs, (g) no dermal–epidermal separation in the sections incubated with anti-COL7 IgG, and (h) no dermal–epidermal separation in the sections incubated 
with anti-COL7 IgG, PMNs, and 25 mg/ml BAY61-3606. (i–l) Representative experiments evaluating the expression of CD66b (x-axis) and L-selectin (CD62L, 
y-axis) in immune complex-stimulated PMNs. (i) CD66b and CD62L expression in resting PMNs show low expression of CD66b and high expression of CD62L. 
Data are based on five experiments per group. (J) By contrast, IC activation leads to L-selectin shedding and increased CD66b expression. (K) Low 
concentrations of BAY61-3606 had no impact on the IC-induced changes in PMN surface molecule expression. (l) Higher compound concentrations normalized 
CD66b expression, but had no effect on L-selectin sheading. (M–P) These effects of BAY61-3606 were achieved at non-toxic concentrations, as evaluated by 
annexin V/propidium iodine staining. Representative results from (M) solvent- (water), (n) UV-irradiated- (positive control), and (O,P) BAY-61-3606-treated 
activated PMNs.
FigUre 7 | Pharmacological inhibition of SYK ablates signaling events in immune complex-activated polymorphonuclear leukocyte (PMN). (a) Representative blots 
from immune complex-activated PMN (“C”) or activated PMNs treated with BAY61-3606 (“BAY”) from three blood donors. (B) Image analysis showed that 
BAY61-3606 ablated pAkt phosphorylation and significantly reduced p38 and Erk phosphorylation. The data are presented as the mean (boxes) and STD (error 
bars) and are based on three experiments per group (*p < 0.05, t-test).
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either anti- or pro-inflammatory effects. In support of the first 
assumption, SYK acts downstream of activating FcγR (44), which 
is essential to mediate inflammation in PD (9, 45) and other 
autoantibody-mediated diseases (46). By contrast, we recently 
identified an inhibitory signaling cascade, triggered by binding 
of highly galactosylated ICs to FcγRIIB and dectin-1 to block 
the pro-inflammatory signaling triggered by C5aR1. Inhibition 
of signaling downstream of C5aR1 was mediated by tyrosine 
phosphorylation of the ITAM-like motif downstream of dectin-1 
and transient phosphorylation of SYK (6). Our results clearly 
document that SYK expression by myeloid, but not lymphoid, 
cells is an absolute requirement for induction of inflammation 
in antibody transfer-induced EBA, which has also been recently 
demonstrated elsewhere (47). In this paper, the authors also 
demonstrated a complete lack of skin lesion in SKY-deficient 
mice, which were generated by injection of bone marrow cells 
of Syktm1Tyb mice into lethally irradiated CD45.1+ recipient wild-
type mice. Hence, also herein, SKY expression on radiosensitive 
(hematopoietic) cells has convincingly been demonstrated. By use 
of myeloid- and lymphoid cell-specific SYK-deficient mice, we 
are here able to link the SYK-dependency to the myeloid cell line-
age (Figures 4 and 5). This is in line with the in vitro observations 
made here (Figure 6) and by Németh et al. who also demonstrated 
a complete unresponsiveness of neutrophils from SYK-deficient 
mice to stimulation with ICs (47). In experimental EBA, myeloid 
and T cells have been demonstrated to mediate skin inflamma-
tion and blistering (7, 48), while mast cells were activated, but not 
required for clinical disease induction (49). Based on the findings 
presented here, myeloid, but not T cell expressed SYK mediates 
EBA pathogenesis. Of these, both neutrophils and monocytes/
FigUre 8 | Plaur and formyl peptide receptor 1 (Fpr1) are regulated by SYK in immune complex-activated murine neutrophils. (a) Neutrophils were activated by 
immune complexes in absence or presence of BAY-61-3606 (BAY). Solvent and resting cells served as controls. Plots represent the expression of indicated gene in 
relation to Gapdh. Because of the non-parametric distribution, data are presented as median (centered vertical line), 25/75-percentile (boxes), and the 
5/95-percentile (bars). Data are based on 8–10 samples per group. Statistical analysis was performed using ANOVA Ranks with the Student–Newman–Keuls 
post-test. (B) mRNA expression of Sykb, Gr-1, Plaur, and Fpr1 were determined in the skin of healthy mice (NR-IgG) and mice with experimental epidermolysis 
bullosa acquisita (EBA) (anti-type VII collagen IgG). For expression analysis, skin specimens from corresponding areas were obtained. Myeloid cell infiltration, 
mirrored by an increase in Gr-1 expression, was accompanied by an increased expression of Sykp, Plaur, and Fpr1. Data are based on five mice per group. 
Statistical calculations were performed using Rank Sum test. (c) Western blot analysis of SYK and GAPDH expression in the same samples of immunization-
induced EBA and normal mouse skin. SYK expression could, in most cases, be detected only in lesional skin—with very few SYK expression in healthy skin. The 
graph shows the relative amount of the mean gray value (MD) of the SYK bands per GAPDH bands. Here representative blots are shown. (D) Quantitative analysis 
of the Western blots from five mice per group (t-test).
FigUre 9 | SYK and downstream kinases are essential to drive inflammation and blistering in experimental epidermolysis bullosa acquisita (EBA). This schematic 
summarizes the current understanding of the events leading to blistering in experimental EBA. (1) The initial event is the binding of the IgG and/or IgA autoantibodies 
directed against type VII collagen (COL7). (2) Thereafter, anaphylatoxins are generated by activation of the complement cascade. Furthermore, several cytokines lipid 
mediators are released, which collectedly leads (3) to the activation of endothelial cells and allows the (4) CD18/ICAM-1-dependent extravasation of Gr-1+ myeloid 
cells into the skin. (5) Within the skin, myeloid cells bind to the skin-bound immune complexes via specific activating Fc gamma receptors (FcγR). (6) FcγR binding 
triggers an intracellular signaling cascade involving SYK, p38, ERK, and Akt, ultimately leading to the activation of the NCF1 gene, which is part of the NADPH 
oxidase complex and generates reactive oxygen species (ROS). Within this pathway, we show an absolute requirement of SYK for blister induction in EBA. Blockade 
of downstream kinases (i.e., p38, Akt, or individual Src family kinases) only partially reduces the blistering phenotype, indicating that SYK activation is in the center 
stage of EBA pathogenesis. (7) Ultimately, this intracellular signaling process leads to the release of ROS and proteases from the myeloid cells, which (8) mediates 
blistering. Image modified from Ludwig et al. (2).
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macrophages, which have been recently been demonstrated to 
contribute to EBA pathogenesis (50), are the two most likely cell 
types expressing SYK and contributing to EBA pathogenesis.
The almost complete absence of dermal myeloid cell infiltration 
after genetic or pharmacologic SYK inhibition is, at first glance, 
puzzling, because ablation of Syk does not greatly impair the 
migration properties of neutrophils (51). Furthermore, similar 
observations were made in mice lacking FcγR IV expression (9). 
We therefore hypothesize that when myeloid cells become activated 
by ICs located at the DEJ, they not only mediate blistering, but also 
release numerous mediators that in turn trigger an amplification 
of myeloid cell recruitment into the skin. So far, this has not been 
formerly demonstrated for EBA. In experimental BP, neutrophil 
elastase degrades collagens, leading to the formation of chemotactic 
peptides, which sustains the influx of neutrophils into the skin (52).
We next aimed to validate the predicted Sykb-gene network 
(Figure 1B). Within the predicted co-expression network, several 
interacting partners of SKY (e.g., Cd300b, Tlr13, Jdp2, and Nfkbid) 
were validated by curated databases (not shown). In addition, 
two novel Sykb-interacting genes, Plaur and Fpr1, were validated. 
Plaur (plasminogen activator, urokinase receptor) is expressed in 
conjunction with the C3-receptor on the surface of neutrophils 
(53). The function of Plaur has been linked to neutrophil migra-
tion (54, 55). Fpr1 is expressed on activated neutrophils and 
promotes further activation upon ligand binding (56).
Our finding adds to the current view of mechanisms leading 
to tissue damage in EBA (2), which is initiated and triggered by 
the binding of IgG/A autoantibodies to COL7. This initial bind-
ing leads to increased concentrations of potent chemoattractants 
such as C5a (57) and leukotriene B4 (58), which lead to a CD18/
ICAM-1-dependent influx of myeloid cells into the skin (7, 8). 
In the skin, myeloid cells bind to the tissue-deposited ICs in an 
FcγRIV-dependent fashion (9). This engagement of FcγR to ICs 
triggers intracellular signaling, involving SYK, PI3Kβ and δ, 
AKT, p38 MAPK, ERK, Src family kinases, CARD9, and RORα 
(10–14, Koga et al., submitted1). Of note, we here demonstrate 
that ERK, AKT, and p38 act downstream of SYK, which is (at 
least) required for ROS release and degranulation (Figure  6). 
The two newly identified interacting genes of Sykb, namely 
Fpr1 and Plaur, most likely also act downstream of Sykb, but 
this awaits experimental confirmation. Collectively, myeloid cell 
activation leads to cytokine release, which sustains further neu-
trophil recruitment (8, 50, 59) and, through release of ROS and 
proteases, induces subepidermal blistering (7, 16). This concept 
1 Koga H, Kasprick A, Lopez R, et al. Therapeutic effect of a novel PI3Kδ inhibitor 
in experimental epidermolysis bullosa acquisita. Front Immunol (2017).
of autoantibody-mediated tissue damage in EBA is graphically 
summarized in Figure 9.
Collectively, these insights into EBA pathogenesis were driven by 
an unbiased expression profiling approach and identified myeloid 
SYK as a central player in driving inflammation in a prototypical 
autoantibody-induced disease. Furthermore, we recognized and 
experimentally validated novel gene interaction partners of SYK, 
specifically Fpr1 and Plaur. This should encourage the exploitation 
of SYK and SYK-regulated genes as potential therapeutic targets 
for EBA, as well as diseases with autoantibody-driven pathology.
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